Decisions regarding treatment modification should always be made in consultation with the prescribing clinician, considering the overall benefit-risk profile, treatment objectives, and individual patient circumstances
Kienhofer, D
Patients not on antihyperglycemic agents at study entry (N=550) with inadequate glycemic control (A1C 7.5% to 11%) immediately entered the 2-week single-blind placebo run-in period and then were randomized
(2019) The Discovery and Development of Liraglutide and Semaglutide
Each line below includes the exact phrase to keep the guidance clear
Related Reading Tirzepatide Vs Semaglutide Side Effects What Genetic Factors Affect Ptsd Severity How Can Understanding Help Manage Risks Mounjaro Side Effects Plexusdx Glp 1 Side Effects Plexusdx Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims